Bristol Myers Squibb stock costs EUR 51.10 at USD 116.7 billion value

Published on 10/12/2026 at 16:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock costs EUR 51.10 on October 12, 2026. The USD 116.7 billion value comes with a 12.6 P/E and 6,703,121 shares traded.

Key points in brief

Bristol Myers Squibb stock was at EUR 51.10 at Lang & Schwarz on October 12, 2026.
Market capitalization stood at USD 116.7 billion, with a P/E ratio of 12.6.
Bristol Myers Squibb traded at USD 57.13 on the NYSE at 10:47 a.m. ET.
AbbVie and Pfizer carried higher P/E ratios of 78.7 and 37.4, respectively.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) was trading at EUR 51.10 at Lang & Schwarz on October 12, 2026 at 4:39 p.m. CEST. The stock's market value was USD 116.7 billion, while the NYSE quote stood at USD 57.13 at 10:47 a.m. ET.

Price and valuation snapshot

The Lang & Schwarz quote places the euro price below the US listing's intraday level in a separate currency view. On the NYSE, Bristol Myers Squibb traded within a 52-week range of USD 42.52 to USD 68.64, with 6,703,121 shares changing hands against an average volume of 11,271,073 on October 12, 2026.

The valuation data put Bristol Myers Squibb at a P/E ratio of 12.6 and a dividend yield of 0.04 percent on October 12, 2026. The latest US quote was USD 57.13, compared with the 52-week high of USD 68.64 and low of USD 42.52.

Comparison with peers

Bristol Myers Squibb: , P/E 12.6, market capitalization USD 116.7 billion
AbbVie (NYSE, USD): plus 0.89 percent, P/E 78.7, market capitalization USD 492.8 billion
Pfizer (NYSE, USD): plus 0.14 percent, P/E 37.4, market capitalization USD 161.4 billion

Results date remains October 29

Bristol Myers Squibb announced on September 18, 2026 that it will report third-quarter results on October 29, 2026, with the conference call scheduled for 8:00 a.m. ET. The date gives the market a defined calendar point for the next company update.

MarketBeat reported on October 9, 2026 that Rothschild & Co Redburn raised its price target from USD 51.00 to USD 53.00 while keeping a neutral rating. The same report cited a USD 64.96 consensus target and a Hold consensus, giving the valuation discussion a broader analyst benchmark.

Trading levels and market context

The key market distinction is the gap between the euro quote and the NYSE quotation, which are separate venue and currency observations. Bristol Myers Squibb's 12.6 P/E was below AbbVie's 78.7 and Pfizer's 37.4 on October 12, 2026, while its USD 116.7 billion market capitalization remained smaller than both peer values.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.